Efferocytosis regulatory factors in atherosclerosis: A preclinical systematic review.
Biochem Biophys Res CommunAug 22, 2026 (epub)
Clinical ResearchCardiology
Yi Zhao, Keying Wu, Hongyang Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review examined 36 preclinical studies to identify 35 endogenous factors regulating efferocytosis in atherosclerosis. The review highlighted metabolic regulators like PKM2 and GLS1, suggesting metabolic reprogramming is crucial for effective efferocytosis and inflammation resolution. Preliminary clinical evidence supports ten factors, with PKM2 being the only biomarker with prospective observational data.
Key findings
- Thirty-five endogenous regulatory factors were identified that influence efferocytosis in atherosclerosis.
- Metabolic regulators such as PKM2 and GLS1 play distinct roles in different stages of efferocytosis.
- Ten factors had preliminary clinical evidence aligning with preclinical findings.
- PKM2 is the only candidate biomarker with prospective observational data, needing further validation.
Why it matters
Understanding the regulatory factors of efferocytosis in atherosclerosis can inform potential therapeutic strategies aimed at enhancing plaque stability and reducing cardiovascular events. Metabolic reprogramming may be a key target for intervention.